Skip to main content

Table 2 Response of Renca-MUC1 tumors to radiation and vaccine and tumor rechallenge

From: Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen

 

aResponders/Cured

bImmune to Rechallenge

cIFN-γ Mean Spots ± SD

 
 

# Mice/Total

Percent

Control

0/36

0%

N/A

N/A

Vaccine

0/7

0%

N/A

N/A

Radiation

2/43

4%

0/6

N/A

Rad + Empty Vector

3/20

15%

3/3

140.4 ± 29.4

Rad + Vaccine (Schedule 1)

11/45

24%

9/9

156.4 ± 24.6

Vaccine + Rad (Schedule 2)

17/29

58%

7/8

152.6 ± 24.1

  1. Data were compiled from three independent experiments
  2. aResponders/Cured: Responders were characterized by inhibition of tumor growth or complete tumor regression
  3. bImmune to rechallenge: Responding and non-responding mice were challenged with 1x105 Renca-MUC1 cells injected in the left flank contralateral to the Renca-MUC1 primary tumor on day 40–60
  4. cIFN-γ: Splenocytes were obtained from mice at 3-4 weeks after tumor rechallenge, stimulated with Renca-MUC1 cells in vitro and tested for production of IFN-γ in an ELISPOT assay
Back to article page